Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities

Abstract Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is frequently diagnosed at advanced stages, limiting curative options. Multi-kinase inhibitors (MKIs), such as sorafenib and lenvatinib, serve as first-line therapies for unresectable HCC. However, the widespread...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Junxin Li, Yu Huang, Jiawei Li, Min Shi, Yi Xiao, Fei Du, Gongli Hu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-01-01
coleção:	Molecular Cancer
Assuntos:	HCC Drug resistance Metabolic reprogramming Glycolysis Lipid metabolism Amino acid metabolism
Acesso em linha:	https://doi.org/10.1186/s12943-026-02578-w
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!